FindTrial
Sign In

Is hyperparathyroidism in Indians a different phenotype compared to the Western world

Clinico-pathological study of symptomatic hyperparathyroidism; is it a different phenotype expression of hyperparathyroidism?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041684
Enrollment
300
Registered
2022-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E213- Hyperparathyroidism, unspecified

Interventions

Intervention1: Nil: NIl

Sponsors

Amrita Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with surgically proven primary hyperparathyroism were included in our study

Exclusion criteria

Exclusion criteria: Patients suspected to have manifestations of multiple endocrine neoplasia were excluded. Patients operated for secondary or tertiary HPT were also excluded

Design outcomes

Primary

MeasureTime frame
Demographic profile, primary symptom, age at the onset of primary symptom, co-morbid diseases, number of parathyroid lesions, histological features of parathyroid lesions 1. Persistent normocalcaemia 2. Recurrent Hypercalcemia 3. Persistent HypercalcemiaTimepoint: Symptoms of patient in Pre op presentation in months and years Post op period in days with 1. Persistent normocalcaemia 2. Recurrent Hypercalcemia 3. Persistent Hypercalcemia—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactRiju Ramachandran

Amrita Institute of Medical Sciences

rijurmenon@gmail.com9447041973

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026